Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 1, 2003, Pages 81-86

  Alvarado, Yesid ^a   Cortes, Jorge ^a   Verstovsek, Srdan ^a   Thomas, Deborah ^a   Faderl, Stephan ^a   Estrov, Zeev ^a   Kantarjian, Hagop ^a   Giles, Francis J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Efficacy; Essential thrombocythemia; Pegylated interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANAGRELIDE; PARACETAMOL;

ADULT; AGED; ALOPECIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEPATITIS; HUMAN; HYPERPLASIA; MALE; MEGAKARYOCYTE; MYALGIA; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; SYMPTOM; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; FEMALE; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET COUNT; POLYETHYLENE GLYCOLS; THROMBOCYTOSIS;

EID: 0037217859     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0533-4     Document Type: Article

References (42)

1. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC Schacter LP (1988) Anagrelide: A new drug for treating thrombocytosis. N Engl J Med 318:1292
2. Tefferi A, Solberg LA, Silverstein MN (2000) A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 109:141
3. Finazzi G, Barbui T (1999) Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol 78:389
4. Tomer A (2002) Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 99:1602
5. Tefferi A, Silverstein MN, Petitt RM, Mesa RA Solberg LA Jr (1997) Anagrelide as a new platelet-lowering agent in essential thrombocythemia: Mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost 23:379
6. Storen EC, Tefferi A (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97:863
7. Oertel MD (1998) Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm 55:1979
8. Giles FJ, Singer CR, Gray AG, Yong KL, Brozovic M, Davies SC, Grant IR, Hoffbrand AV, Machin SJ, Mehta AB, et al (1988) Alpha-interferon therapy for essential thrombocythaemia. Lancet 2:70
9. Giles FJ (1991) Maintenance therapy in the myeloproliferative disorders: The current options. Br J Haematol 79 [Suppl 1]:92
10. Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E Radaszkiewicz T (1989) Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1:634
11. Bentley M, Taylor K, Grigg A, Kronenberg H, Gibson J, Bunce I, Eliadis P, Olsen T, Wright S, Taylor D, Rodwell R (1999) Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia. Leuk Lymphoma 36:123
12. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W Ludwig H (1991) Interferon in essential thrombocythaemia. Br J Haematol 79 [Suppl 1]:42
13. Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J Bordens R (2001) Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res 21:1103
14. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF (2000) Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 39:10634
15. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP (2000) A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 32:647
16. Perry CM, Jarvis B (2001) Peginterferon-alpha-2a (40 kD): A review of its use in the management of chronic hepatitis C. Drugs 61:2263
17. Kozlowski A, Charles SA Harris JM (2001) Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs 15:419
18. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK (2001) A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395
19. Michiels JJ, Juvonen E (1997) Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 23:339
20. Briere J, Guilmin F (2001) Management of patients with essential thrombocythemia: Current concepts and perspectives. Pathol Biol (Paris) 49:178
21. Wang Q, Miyakawa Y, Fox N Kaushansky K (2000) Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 96:2093
22. Drachman JG, Kaushansky K (1997) Dissecting the thrombopoietin receptor: Functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci U S A 94:2350
23. Hilton DJ (1999) Negative regulators of cytokine signal transduction. Cell Mol Life Sci 55:1568
24. Alexander WS, Starr R, Metcalf D, Nicholson SE, Farley A, Elefanty AG, Brysha M, Kile BT, Richardson R, Baca M, Zhang JG, Willson TA, Viney EM, Sprigg NS, Rakar S, Corbin J, Mifsud S, DiRago L, Cary D, Nicola NA, Hilton DJ (1999) Suppressors of cytokine signaling (SOCS): Negative regulators of signal transduction. J Leuk Biol 66:588
25. Sacchi S, Gugliotta L, Papineschi F, Liberati AM, Rupoli S, Delfini C, Ruggeri M, Cavanna L, Bucalossi A, Benedetti E, Ferrandina C, Vinci G, Morselli M, Torelli G (1998) Alfa-interferon in the treatment of essential thrombocythemia: Clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia 12:289
26. Velu T, Delwiche F (1988) Treatment of essential thrombocythaemia by alpha-interferon. Lancet 2:628
27. Kasparu H, Bernhart M, Krieger O, Lutz D (1992) Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia. Eur J Haematol 48:33
28. Sacchi S, Tabilio A, Leoni P, Riccardi A, Vecchi A, Messora C, Bensi L, Falzetti F, Rupoli S Ucci G, et al (1993) Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment. Ann Hematol 66:245
29. Vantroyen B, Vanstraelen D (2002) Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. Acta Haematol 107:158
30. Cincotta R, Higgins JR, Tippett C, Gallery E, North R, McMahon LP, Brennecke SP (2000) Management of essential thrombocythaemia during pregnancy. Aust N Z J Obstet Gynaecol 40:33
31. Iki S, Usuki K, Kotaki M, Yamaguchi Y, Urabe A (1999) Successful pregnancy and delivery during alpha-interferon therapy for essential thrombocythemia (in Japanese). Rinsho Ketsueki 40:1201
32. Delage R, Demers C, Cantin G, Roy J (1996) Treatment of essential thrombocythemia during pregnancy with interferon-alpha. Obstet Gynecol 87:814
33. Milano V, Gabrielli S, Rizzo N, Vianelli N, Gugliotta L, Orsini LF, Baravelli S, Pilu GL, Bovicelli L (1996) Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. J Matern Fetal Med 5:74
34. Williams JM, Schlesinger PE, Gray AG (1994) Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon. Br J Haematol 88:647
35. Vianelli N, Gugliotta L, Tura S, Bovicelli L, Rizzo N Gabrielli A (1994) Interferon-alpha 2a treatment in a pregnant woman with essential thrombocythemia. Blood 83:874
36. Thornley S, Manoharan A (1994) Successful treatment of essential thrombocythemia with alpha interferon during pregnancy. Eur J Haematol 52:63
37. Grossberg SE, Kawade Y, Kohase M, Klein JP (2001) The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: The tenfold reduction unit. J Interferon Cytokine Res 21:743
38. Oberg K, Alm G (1997) The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors. Biotherapy 10:1
39. Steinmann GG, God B, Rosenkaimer F, Adolf G, Bidlingmaier G, Fruhbeis B, Lamche H, Lindner J, Patzelt E, Schmahling C, et al (1992) Low incidence of antibody formation due to long-term interferon-alpha 2c treatment of cancer patients. Clin Investig 70:136
40. McSweeney EN, Giles FJ, Worman CP, Jewel AP, Tsakona CP, Hoffbrand AV, Mehta AB, Newland AC, Cawley JC, Galvani D, et al (1993) Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia. Br J Haematol 85:77
41. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J (2000) Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673
42. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666